Whitehawk Therapeutics (WHWK) EBIAT (2018 - 2025)
Whitehawk Therapeutics (WHWK) has disclosed EBIAT for 8 consecutive years, with -$23.3 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 27.12% to -$23.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.6 million through Dec 2025, up 67.67% year-over-year, with the annual reading at -$20.6 million for FY2025, 67.66% up from the prior year.
- EBIAT for Q4 2025 was -$23.3 million at Whitehawk Therapeutics, down from -$17.7 million in the prior quarter.
- The five-year high for EBIAT was $73.0 million in Q1 2025, with the low at -$87.1 million in Q3 2021.
- Average EBIAT over 5 years is -$16.0 million, with a median of -$16.1 million recorded in 2021.
- The sharpest move saw EBIAT plummeted 2911.34% in 2021, then skyrocketed 499.23% in 2025.
- Over 5 years, EBIAT stood at -$16.0 million in 2021, then grew by 13.04% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then dropped by 12.43% to -$18.3 million in 2024, then fell by 27.12% to -$23.3 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$23.3 million, -$17.7 million, and -$52.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.